NewsBenzingaSutro Biopharma: BPA del tercer trimestre de $(1.90) supera la estimación de $(1.91); ventas de $9.100 millones no alcanzan la estimación de $10.342 millones Sutro Biopharma: BPA del tercer trimestre de $(1.90) supera la estimación de $(1.91); ventas de $9.100 millones no alcanzan la estimación de $10.342 millones Benzinga 2026.11.12 21:41 (GMT+0) Open on Benzinga Other news Swoosh and a Miss: Nike Investor Day Leaves Wall Street Cold-Footed Wall Street Says the AI Trade Is Over — ETF Investors Aren’t Acting Like It Citigroup Maintains Neutral on Westlake, Lowers Price Target to $65 Citigroup Maintains Neutral on LyondellBasell Industries, Lowers Price Target to $66 Caterpillar's 'Best-In-Class' Construction Business Is Getting Overlooked, Analyst Says How to Play NKE Stock as Nike Risks Becoming a Forever Turnaround Story